Literature DB >> 32384148

Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing.

Navisha Dookie1,2, Nesri Padayatchi1,2, Richard J Lessells1,3, Cherise L Naicker1,2, Sunitha Chotoo4, Kogieleum Naidoo1,2.   

Abstract

A case of multidrug-resistant tuberculosis is presented. It highlights the role of whole-genome sequencing, expanded phenotypic drug susceptibility testing, and enhanced case management, offering a more complete understanding of drug susceptibility to Mycobacterium tuberculosis. This approach guides an effective individualized treatment strategy that results in rapid sustained culture conversion.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  Mycobacterium tuberculosis; individualised treatment; multi-drug resistant tuberculosis; whole genome sequencing

Year:  2020        PMID： 32384148      PMCID： PMC7778351          DOI： 10.1093/cid/ciaa526

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.

Authors:  Francesca Conradie; Andreas H Diacon; Nosipho Ngubane; Pauline Howell; Daniel Everitt; Angela M Crook; Carl M Mendel; Erica Egizi; Joanna Moreira; Juliano Timm; Timothy D McHugh; Genevieve H Wills; Anna Bateson; Robert Hunt; Christo Van Niekerk; Mengchun Li; Morounfolu Olugbosi; Melvin Spigelman
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

Review 2.  Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.

Authors:  R P G van Heeswijk; B Dannemann; R M W Hoetelmans
Journal:  J Antimicrob Chemother       Date:  2014-05-23       Impact factor: 5.790

3.  Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis.

Authors:  David W Dowdy; Grant Theron; Jeffrey A Tornheim; Robin Warren; Emily A Kendall
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

4.  The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.

Authors:  José A Caminero; Alberto L García-Basteiro; Adrián Rendon; Alberto Piubello; Emanuele Pontali; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2019-10-10       Impact factor: 16.671

5.  Molecular-based tuberculosis drug susceptibility testing: one size fits all?

Authors:  D Chesov; C Lange; J Heyckendorf
Journal:  Int J Tuberc Lung Dis       Date:  2019-08-01       Impact factor: 2.373

6.  Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Authors:  Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione
Journal:  Lancet Infect Dis       Date:  2016-07-07       Impact factor: 25.071

Review 7.  Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.

Authors:  Navisha Dookie; Santhuri Rambaran; Nesri Padayatchi; Sharana Mahomed; Kogieleum Naidoo
Journal:  J Antimicrob Chemother       Date:  2018-05-01       Impact factor: 5.790

8.  Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms.

Authors:  Claudio U Köser; Daniela Maria Cirillo; Arash Ghodousi; Elisa Tagliani; Eranga Karunaratne; Stefan Niemann; Jennifer Perera
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

9.  Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.

Authors:  Margaretha de Vos; Serej D Ley; Kristin B Wiggins; Brigitta Derendinger; Anzaan Dippenaar; Melanie Grobbelaar; Anja Reuter; Tania Dolby; Scott Burns; Marco Schito; David M Engelthaler; John Metcalfe; Grant Theron; Annelies van Rie; James Posey; Rob Warren; Helen Cox
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

10.  Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations.

Authors:  Pauline Lempens; Conor J Meehan; Koen Vandelannoote; Kristina Fissette; Pim de Rijk; Armand Van Deun; Leen Rigouts; Bouke C de Jong
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379
  10 in total
  2 in total

1.  Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.

Authors:  Sadia Shakoor; Safina Abdul Razzak; Dania Khalid Saeed; Zahra Hasan; Saba Faraz Sabzwari; Zahida Azizullah; Akbar Kanji; Asghar Nasir; Samreen Shafiq; Najia Karim Ghanchi; Rumina Hasan
Journal:  BMC Microbiol       Date:  2022-02-25       Impact factor: 3.605

2.  Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial.

Authors:  Annelies Van Rie; Elise De Vos; Emilyn Costa; Lennert Verboven; Felex Ndebele; Tim H Heupink; Steven Abrams; Boitumelo Fanampe; Anneke Van der Spoel Van Dyk; Salome Charalambous; Gavin Churchyard; Rob Warren
Journal:  Trials       Date:  2022-10-08       Impact factor: 2.728
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.